The PALB2 p.Leu939Trp mutation is not associated with breast cancer risk.
IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, via Adamello 16, 20139, Milan, Italy. irene.catucci@ifom.eu.
Irene
I
Catucci
Unit of Molecular Bases of Genetic Risk and Genetic Testing, Department of Preventive and Predictive Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Paolo
P
Radice
Cancer Epidemiology Centre, Cancer Council Victoria, Melbourne, Victoria, Australia.|Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Victoria, Australia.
Roger L
RL
Milne
Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, Minnesota, USA.
Fergus J
FJ
Couch
Genetic Epidemiology Laboratory, Department of Pathology, The University of Melbourne, Parkville, Australia.
Melissa C
MC
Southey
IFOM, Fondazione Istituto FIRC di Oncologia Molecolare, via Adamello 16, 20139, Milan, Italy.
Paolo
P
Peterlongo
D019313:BRCA1 Protein / Q000235:genetics; D024682:BRCA2 Protein / Q000235:genetics*; D001943:Breast Neoplasms; D000076164:Fanconi Anemia Complementation Group N Protein; D020022:Genetic Predisposition to Disease; D006801:Humans; D009154:Mutation; D012306:Risk; D025521:Tumor Suppressor Proteins / Q000235:genetics
D019313:BRCA1 Protein; D024682:BRCA2 Protein; D000076164:Fanconi Anemia Complementation Group N Protein; C512790:PALB2 protein, human; D025521:Tumor Suppressor Proteins
Breast cancer genetic risk factor; Breast cancer predisposition; PALB2 p.Leu939Trp; VUS